Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2015
Q1
$18.2M Buy
113,732
+25,424
+29% +$4M 0.19% 159
2014
Q4
$14.1M Sell
88,308
-30,460
-26% -$4.75M 0.15% 178
2014
Q3
$16.7M Sell
118,768
-15,863
-12% -$2.07M 0.23% 124
2014
Q2
$15.9M Buy
134,631
+90,821
+207% +$10.5M 0.22% 123
2014
Q1
$5.4M Sell
43,810
-3,175
-7% -$385K 0.08% 251
2013
Q4
$5.36M Sell
46,985
-1,304
-3% -$148K 0.09% 242
2013
Q3
$5.41M Sell
48,289
-400
-0.8% -$43.4K 0.1% 240
2013
Q2
$4.8M Buy
+48,689
New +$5.05M 0.1% 246

Other funds holding AMGN

Baird's AMGN Position: Q1 2015 in Review

Baird increased its Amgen (AMGN) stake by 29% in Q1 2015, buying an estimated $4M and bringing the position to 113,732 shares worth $18.2M. The position accounts for 0.19% of the portfolio, ranked #159.

Baird first reported a position in AMGN in Q2 2013 and has held it in 8 quarters since. 1,344 funds tracked by Wall St. Rank hold AMGN as of Q1 2015.

  • Baird held 113,732 shares of Amgen worth $18.2M as of Q1 2015.
  • Baird bought 25,424 Amgen shares in Q1 2015, an estimated $4M.
  • Amgen made up 0.19% of Baird's portfolio in Q1 2015, its #159 holding.
  • Baird first reported a position in Amgen in Q2 2013 and has held it in 8 quarters since.
  • 1,344 funds tracked by Wall St. Rank held Amgen as of Q1 2015.

Based on Baird's 13F filing for Q1 2015, filed 13 May 2015.